ArticleJournal of immunology (Baltimore, Md. : 1950)2000
Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.
Article in Journal of immunology (Baltimore, Md. : 1950), 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Exploratory Study: Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients
Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
Who cites it
56 citing papers in PubMed, 168 citations in OpenAlex.
- The Impact of Targeting TRAF2 and NCK-Interacting Protein Kinase on Antitumor Effect and Tumor Immune Environment in c-MYC-High SCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Article
- Identification, sorting and profiling of functional killer cells via the capture of fluorescent target-cell lysate.Nature biomedical engineering · 2024Article
- Bidirectional crosstalk between therapeutic cancer vaccines and the tumor microenvironment: Beyond tumor antigens.Fundamental research · 2023Review
- The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment.Frontiers in immunology · 2022Review
- Augmenting Vaccine Immunogenicity through the Use of Natural Human Anti-rhamnose Antibodies.ACS chemical biology · 2018Article
- The opposing roles of CD4Immunology · 2018Review
- CD4 and CD8 T lymphocyte interplay in controlling tumor growth.Cellular and molecular life sciences : CMLS · 2018Review
- Prognostic significance of CD4 and interleukin-22 expression in pancreatic cancer.International journal of clinical and experimental pathology · 2017Article
- Novel vaccines for glioblastoma: clinical update and perspective.Immunotherapy · 2016Review
- Translational aspects in targeting the stromal tumour microenvironment: from bench to bedside.New horizons in translational medicine · 2016Article
- Mouse model for pre-clinical study of human cancer immunotherapy.Current protocols in immunology · 2015Article
- A top-down view of the tumor microenvironment: structure, cells and signaling.Frontiers in cell and developmental biology · 2015Review
- Harnessing the Microbiome to Enhance Cancer Immunotherapy.Journal of immunology research · 2015Review
- T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation.European journal of immunology · 2014Article
- Re-adapting T cells for cancer therapy: from mouse models to clinical trials.Immunological reviews · 2014Review
- CD4 T-cell immunotherapy for chronic viral infections and cancer.Immunotherapy · 2013Review
- MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR.Cancer immunology, immunotherapy : CII · 2013Article
- Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies.Frontiers in immunology · 2013Article
- Profound tumor-specific Th2 bias in patients with malignant glioma.BMC cancer · 2012Article
- NFAT1 supports tumor-induced anergy of CD4(+) T cells.Cancer research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Neoantigens resulting from the inherent genomic instability of tumor cells generally do not trigger immune recognition. Similarly, transfection of tumors with model Ags often fails to elicit CD8+ T cell responses or alter a tumor's growth rate or lethality. We report here that the adoptive transfer of activated Th1-type CD4+ T cells specific for a model tumor Ag results in the de novo generation of CD8+ T cells with specificity to that Ag and concomitant tumor destruction. The anti-tumor effects of the CD4+ T cells required the presence of both MHC class I and class II on host cells, as evidenced by experiments in knockout mice, suggesting that CD4+ T cells enhanced the ability of host APC to activate endogenous CD8+ T cells. These results indicate that the apparent inability of tumor cells expressing highly immunogenic epitopes to activate tumor-specific CD8+ T cells can be altered by activated CD4+ T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.